Slides
Page 1
CHI MERIC THE RAPEUTICS CONFID ENTIAL . NOT FOR DI STRI BUTI ON CHIMERIC PIONEERS IN CELL THERAPY CHM ASX:
Page 2
CHI MERIC THE RAPEUTICS CONFID ENTIAL . NOT FOR DI STRI BUTI ON. Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward- looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law. This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company. DISCLAIMER 2
Page 3
CHI MERIC THE RAPEUTICS CONFID ENTIAL . NOT FOR DI STRI BUTI ON3 Exchange Share Price 52 Week Range Market Cap Shares on issue IPO 2021 ASX: CHM $0.005 $0.004 - 0.047 ~$1.6B CORPORATE PROFILE INVESTMENT HIGHLIGHTS 4 4 Phase 1 clinical trials Multiple clinical updates Experienced leadership team the ONLY CDH17 CAR-T in clinical trials First in class Robust and long life Approx 10m
Page 4
CHI MERIC THE RAPEUTICS CONFID ENTIAL . NOT FOR DI STRI BUTI ON. 4 3 Novel cell therapies; 4 Clinical Trials CHM CDH17 CAR-T CHM CLTX CAR-T CHM CORE-NK ‘OFF THE SHELF’ NK PHASE 1/2 TRIAL OPEN 3 sites active PHASE 1B TRIAL OPEN 1 site active PHASE 1B TRIAL OPEN PHASE 1B TRIAL OPEN MD Anderson Case Western CHM: BROAD PORTFOLIO
Page 5
CHI MERIC THE RAPEUTICS CONFID ENTIAL . NOT FOR DI STRI BUTI ON CHM CDH17 CHM ASX:
Page 6
CHI MERIC THE RAPEUTICS CONFID ENTIAL . NOT FOR DI STRI BUTI ON. 6 The first CDH17 CAR -T cell therapy in clinical trials in the world CHM CDH17 CAR-T CHM CDH17 CAR-T targets an antigen on the surface/cell membrane of many cancer cells, called CDH17. Our CAR-T is unique, being the first CAR-T cell therapy under development, attacking this target. The current Phase 1/2 trial is the culmination of ten years R&D at the University of Pennsylvania(UPenn) from the lab of the world pioneer in CAR-T cell therapy, Prof Carl June. CHM CDH17 CAR-T OVERVIEW
Page 7
CHI MERIC THE RAPEUTICS CONFID ENTIAL . NOT FOR DI STRI BUTI ON. 7 PHASE 1/2 TRIAL OPEN RAPIDLY RECRUITING Phase 1/2 open at 4 sites: UPENN, Sarah Cannon , Emory and UChicago Cancer Targets: Gastric, Neuroendocrine Tumours and Colorectal 15 patients to be recruited: 4 patients dosed to date 3 more patients manufactured pending dosing 5 patients on waiting list Encouraging early efficacy signals in Patient 2 with Neuroendocrine Tumour CHM CDH17 CAR-T PHASE 1/2 RAPIDLY RECRUITING
Page 8
CHI MERIC THE RAPEUTICS CONFID ENTIAL . NOT FOR DI STRI BUTI ON. 8CLINICAL PRELIMINARY RESULTS 50m Cells Tumour Type Status Patient 1 CRC Lost to follow up Patient 2 NET Stable Disease until day 150 minor progression Patient 3 CRC Stable Disease day 90 Patient 4 CRC Progressive Disease CRC= Colorectal Cancer (Bowel Cancer) NET= NeuroEndocrine Tumor (Intestinal NET) CHM CDH17 DOSE LEVEL 1
Page 9
CHI MERIC THE RAPEUTICS CONFID ENTIAL . NOT FOR DI STRI BUTI ON. WHAT’S NEXT? Safety clearance to Dose Level 2 Patient 5,6,7 manufactured Commence dose level 2 – single dose of 150m cells Monitor safety for 28days for patient 5 (FDA requirement) Patient 5 Patient 6 Patient 7 28 days 7 days EXAMPLE ONLY: Patient 5 June 1 – Day 0 Dose lvl 2 June 28 – DLT period ends 28 day scan This is an example and not a defined timeline of results
Page 10
CHI MERIC THE RAPEUTICS CONFID ENTIAL . NOT FOR DI STRI BUTI ON CHM CORE-NK CHM ASX:
Page 11
CHI MERIC THE RAPEUTICS CONFID ENTIAL . NOT FOR DI STRI BUTI ON. 11 Phase 1b clinical trials being lead by partner institutions OFF THE SHELF: AKA ALLOGENEIC NK cell expansion platform: Universal Donor Positive Phase 1A Clinical Trialin Colorectal Cancer (CRC) and Acute Myeloid Leukaemia (AML) Two ongoing Phase 1B Clinical Trialsin AML and CRC AML: Cohort 1 cleared, moved to dose expansion for Cohort 2; up to 20 patients frontline Our partners MD Anderson and Case Western are supporting the majority share of the cost of these two trials CHM CORE-NK OVERVIEW CHM CORE-NK ‘OFF THE SHELF’ NK PHASE 1B TRIAL OPEN PHASE 1B TRIAL OPEN MD Anderson Case Western
Page 12
CHI MERIC THE RAPEUTICS CONFID ENTIAL . NOT FOR DI STRI BUTI ON. CHM CORE-NK + AZA + VEN in front-line Acute Myeloid Leukaemia Clinical Trials.gov Identifier: NCT05834244 AML PHASE 1B COMBINATION CLINICAL TRIAL OPEN CORE NK CELLS FDA REGISTERED CHEMOTHERAPY FDA REGISTERED BLOOD CANCER DRUG Funded by our partners MD Anderson Cancer Center
Page 13
CHI MERIC THE RAPEUTICS CONFID ENTIAL . NOT FOR DI STRI BUTI ON. 13 Complete response in AML in two patient of first three dosed CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS DIAGNOSIS: AML Not eligible for Chemo or Stem Cell Transplant SAFETY: No dose limiting toxicities, no cytokine release syndrome, no GvHD 2 / 3 patients CORE-NK INFUSION Patient Doses + SOC DAY 28 COMPLETE RESPONSE i CRi = no signs of cancer in response to treatment Blood count yet to recover (standard for AML patients )
Page 14
CHI MERIC THE RAPEUTICS CONFID ENTIAL . NOT FOR DI STRI BUTI ON CHIMERIC PIONEERS IN CELL THERAPY investors@chimerictherapeutics.Com CHM ASX: